title: SAMHD1 is a barrier to antimetabolite-based cancer therapies.
abstract: The outcome of acute myelogenous leukemia (AML) therapy depends on the propensity of leukemic blasts to accumulate ara-CTP, the active triphosphate of cytarabine (ara-C). We identified sterile α motif and HD domain-containing protein 1 (SAMHD1) as an ara-CTPase that protects cancer cells from cytarabine-induced toxicity. Therefore, we propose targeting SAMHD1 as a strategy to potentiate cytarabine and possibly other antimetabolite-based therapies.
authors.affiliation: Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet , Stockholm, Sweden.
authors.forename: Sean G
authors.identifier: 0000-0002-4368-3855
authors.initials: SG
authors.lastname: Rudd
authors.affiliation: Department of Infectious Diseases, Virology, University Hospital Heidelberg , Heidelberg, Germany.
authors.forename: Torsten
authors.identifier: 0000-0001-9597-4112
authors.initials: T
authors.lastname: Schaller
authors.affiliation: Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; Theme of Children´s and Women´s Health, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
authors.forename: Nikolas
authors.identifier: 0000-0001-9468-4543
authors.initials: N
authors.lastname: Herold
keywords: AML; SAMHD1; Vpx; ara-C; cancer; leukemia